FLUBENOL 5 % W/W PREMIX FOR MEDICATED FEEDING STUF
Land: Írland
Tungumál: enska
Heimild: HPRA (Health Products Regulatory Authority)
Vara einkenni
(SPC)
05-06-2024
Sum skjöl fyrir þessa vöru eru ekki tiltæk eins og er, þú getur sent beiðni til þjónustu við viðskiptavini okkar og við munum láta þig vita um leið og við getum fengið þau.
Senda beiðni.
Senda beiðni.
Virkt innihaldsefni:
FLUBENDAZOLE
Fáanlegur frá:
Janssen Cilag Ltd.
ATC númer:
QP52AC12
Skammtar:
5 %w/w
Lyfjaform:
Premix for Med.Feedstuffs
Meðferðarhópur:
Endoparasiticide
Lækningarsvæði:
Fowl - Chicken
Leyfisdagur:
1989-10-01
Vara einkenni
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Flubenol 5 % w/w Premix for Medicated Feeding Stuff
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
For a full list of excipients see section 6.1.
3 PHARMACEUTICAL FORM
Premix for medicated feeding stuff.
White powder.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Pig and Poultry.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Flubendazole is a broad spectrum anthelmintic, effective against mature and immature stages of the following
nematodes of the gastro-intestinal and respiratory tract:
In pigs: _Ascaris suum, _(large roundworm) including migrating larvae, _Hyostrongylus rubidus, _(red stomach worm),
_Oesophagostomum dentatum _(nodular worm). _Trichuris suis _(whipworm), _Strongyloides ransomi _(adult) and
_Metastrongylus apri _(lungworm).
In poultry: _Syngamus trachea, Ascaridia galli, Heterakis gallinarum, Capillaria gallinarum, Amidostomum anseris,_
_Trichostrongylus tenuis._
Flubendazole is ovicidal.
4.3 CONTRAINDICATIONS
Do not use in animals with known hypersensitivity to the active ingredient.
Each g contains:
Active substance
Flubendazole
50 mg
Excipients
Titanium Dioxide (E171) 20 mg
IRISH MEDICINES BOARD
________________________________________________________________________________________________________________________
_Date Printed 21/02/2011_
_CRN 7010260_
_page number: 1_
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Care should be taken to avoid the following practices because they increase the risk of development of resistance and
could ultimately result in ineffective therapy:
•
Too frequent and repeated use of anthelmintics from the same class, over an extended period of time.
•
Underdosing.
Suspected clinical cases of resistance to anthelmintics should be further investigated using appropriate tests (e.g. Faecal Egg
Count
Lestu allt skjalið
